Stem Cell Therapy for Liver Cirrhosis

What This Article Covers

This page looks specifically at what clinical evidence shows about mesenchymal stem cell (MSC) therapy as a treatment for liver cirrhosis — the scarring and loss of function that follows chronic liver damage — rather than the underlying biology of fibrosis. It covers real trial results, changes in standard liver-health measures like the MELD score, safety data, and today's regulatory reality, so people researching this option can separate genuine, evidence-backed progress from hype.

How It's Thought to Work

In cirrhosis, healthy liver tissue is progressively replaced by scar tissue, impairing the liver's ability to filter blood, produce proteins like albumin, and process toxins. Mesenchymal stem cells — most often sourced from umbilical cord tissue or bone marrow — are infused into the bloodstream or, in some trials, directly into the hepatic artery or portal vein. Researchers believe MSCs work less by directly rebuilding liver tissue and more by releasing anti-inflammatory and anti-fibrotic signals that calm the immune response and support the liver's own regenerative capacity. This remains a working hypothesis refined through ongoing trials rather than a fully settled mechanism.

What the Evidence Shows

The clinical picture here is genuinely encouraging in places — with real limits. A 2023 systematic review and meta-analysis in Stem Cell Research & Therapy, pooling 11 clinical trials — including 174 MSC-treated patients and 232 controls in its MELD-score analysis — found that MSC therapy significantly lowered MELD scores at one, two, and six months and raised albumin levels at two weeks and at one, three, and six months, with bilirubin also improving at several of the same intervals. Notably, the analysis found no increase in liver cancer (HCC) risk and reported no severe adverse effects across the included studies — a meaningful safety signal, even as the authors were clear that more high-quality randomized trials are still needed.

A separate, longer-running randomized controlled trial published in Hepatology International followed 219 patients with hepatitis B-related decompensated cirrhosis (108 treated with umbilical cord MSCs, 111 controls) for up to 75 months. There was no survival difference in the first 13 months, but from month 13 to 75, overall survival was significantly higher in the MSC group (hazard ratio 3.68, p=0.005) — a hopeful, hard-won result from one of the field's few long-duration studies. Side effects were minimal: only seven of 108 treated patients had brief, self-resolving fever within hours of infusion, with no other short-term adverse effects and no increase in liver cancer risk over the full 75-month follow-up.

A 2025 review of the clinical trial landscape notes that more than 50 registered trials worldwide — mostly in China, Iran, South Korea, and India — are currently testing MSC approaches for cirrhosis at various phases. That same review cautioned that trial designs vary widely, follow-up periods remain short by chronic-disease standards, and many infused cells are trapped in the lungs before reaching the liver — a real biological hurdle researchers are still working to overcome.

Who Might Be a Candidate

Because MSC therapy for cirrhosis remains investigational, "candidacy" today generally means eligibility for a registered clinical trial rather than a standard-of-care treatment decision. People who may want to discuss this option with a hepatologist or trial coordinator include those who:

• Have compensated or decompensated cirrhosis from causes studied in trials, such as hepatitis B or C, alcohol-related liver disease, or fatty liver disease
• Have not adequately responded to standard medical management
• Are not currently eligible for, or are awaiting, liver transplantation
• Are willing to participate in a monitored research setting with long-term follow-up
• Understand that outcomes vary and that this is not an FDA-approved or guaranteed treatment

Anyone considering this route should search ClinicalTrials.gov for currently enrolling studies and discuss risks and realistic expectations with their liver specialist first.

Bottom Line

The evidence for MSC therapy in liver cirrhosis is more promising than for many experimental regenerative treatments — multiple trials show real improvements in liver function scores and, in at least one long-term study, in survival, with a favorable short-term safety record. But no stem cell product is FDA-approved for cirrhosis, study sizes remain modest, and researchers themselves say larger, longer randomized trials are needed before this becomes a standard option. For now, it's a legitimate and active area of research worth watching closely, not a proven cure available outside of clinical trials.